Gemcitabine hydrochloride injection

DRUG4 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Conditions

Advanced Biliary CancerAdvanced Endometrial CancerMetastatic Pancreatic Ductal AdenocarcinomaRecurrent / Metastatic Nasopharyngeal CancerSarcoma of Uterus

Phase 1

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recurrent / Metastatic Nasopharyngeal Cancer

Start: 2022-01-31End: 2023-08-31Target: 90Updated: 2022-01-21

Phase 2

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

TerminatedNCT05481645

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Endometrial Cancer, Sarcoma of Uterus

Start: 2022-08-26End: 2025-11-30Updated: 2026-01-09

Phase 3

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Biliary Cancer

Start: 2021-02-04End: 2023-02-01Target: 392Updated: 2021-03-22

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

RecruitingNCT07165951

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2025-12-02End: 2028-12-31Target: 566Updated: 2025-12-24

Related Papers

Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial.

Journal of Clinical Oncology2025-05-28